Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 10

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 10
---
 and in combination across disease settings in patients with DLBCL and FL were presented at the 30th European Hematology Association (EHA) Congress. Two oral presentations featured data from the Phase 1/2 EPCORE NHL-2 (NCT04663347) trial evaluating epcoritamab plus rituximab and ifosfamide-carboplatin-etoposide (R-ICE) in patients with relapsed/refractory DLBCL eligible for autologous stem cell transplantation, and the Phase 1/2 EPCORE NHL-5 (NCT05283720) trial evaluating epcoritamab plus polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) in previously-untreated patients with DLBCL. Additionally, results from the Phase 1/2 EPCORE NHL-1 (NCT03625037) and NHL-3 (NCT04542824) trials, including three years of follow-up in patients with relapsed/refractory DLBCL and FL treated with epcoritamab monotherapy, were presented as posters.

• June: Twenty-eight data presentations, including one oral presentation, were featured at the 18th International Conference on Malignant Lymphoma (ICML).

Tivdak (tisotumab vedotin) – First and only ADC for recurrent or metastatic cervical cancer in the U.S., Europe and Japan

• An ADC directed to TF, a protein highly prevalent in solid tumors, including cervical cancer, which is associated with poor prognosis

• Tisotumab vedotin, approved as Tivdak, is the first and only ADC approved in the U.S., Europe and Japan for the treatment of recurrent or metastatic cervical cancer after prior therapy and is the only ADC with demonstrated overall survival data in this setting compared to chemotherapy

• Co-developed globally and co-promoted in the U.S. in collaboration with Pfizer, exclusively by Genmab outside of the U.S. and China

Tisotumab vedotin is an ADC composed of Genmab’s human monoclonal antibody directed to TF and Pfizer’s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E to the antibody. Genmab